Laboratory of Neuroscience and Immunotherapy, University of Medicine and Pharmacy at Hochiminh city, Ho Chi Minh City, Vietnam.
Department of Molecular Oncology, City Children's Hospital, Ho Chi Minh City, Vietnam.
Mol Carcinog. 2019 Nov;58(11):1998-2007. doi: 10.1002/mc.23091. Epub 2019 Jul 31.
Aggressive, high-risk neuroblastoma (NB) exhibits an immature differentiation state, profound epigenetic dysregulation and high telomerase activity. It has been suggested that aggressive NB may be treatable by inducing differentiation whereas therapeutic targeting of telomerase is under investigation for multiple cancer types. While epigenetic regulation of the telomerase reverse transcriptase (TERT) promoter has been described in high-risk NB, the exact molecular mechanisms are still not completely understood. Here we used quantitative real-time polymerase chain reaction (PCR), chromatin immunoprecipitation qPCR, quantitative telomeric repeat amplification protocol, and immunoblot techniques to investigate epigenetic regulation of TERT in wild-type and genetically modified NB cell lines. We demonstrated that TERT expression is reduced during 13-cis retinoic acid-induced NB differentiation and that this inversely correlated with increased expression of AT-rich interaction domain 1A (ARID1A), a subunit of the SWItch/sucrose nonfermentable chromatin remodeling complex. We showed that ARID1A directly caused suppression of TERT and was reliant on DNA binding and co-occupancy of the TERT promoter by the SIN3 transcription regulator family member A (SIN3A) repressor complex allowing NB differentiation to proceed. Finally, using data from NB patient cohorts, we reported a significant correlation between low ARID1A expression, elevated expression of TERT, and poorly differentiated, high-risk NB. These results provide insights into a key epigenetic pathway responsible for modulating TERT-driven NB progression, which could represent a target for therapeutic intervention.
侵袭性、高危神经母细胞瘤(NB)表现出不成熟的分化状态、深刻的表观遗传失调和高端粒酶活性。有人提出,通过诱导分化,侵袭性 NB 可能是可治疗的,而端粒酶的治疗靶向正在针对多种癌症类型进行研究。虽然高危 NB 中已经描述了端粒酶逆转录酶(TERT)启动子的表观遗传调控,但确切的分子机制仍不完全清楚。在这里,我们使用定量实时聚合酶链反应(PCR)、染色质免疫沉淀 qPCR、定量端粒重复扩增协议和免疫印迹技术来研究野生型和基因修饰的 NB 细胞系中 TERT 的表观遗传调控。我们证明,在 13-顺式视黄酸诱导的 NB 分化过程中,TERT 表达减少,这与 AT 丰富相互作用域 1A(ARID1A)的表达增加呈负相关,ARID1A 是 SWItch/sucrose 非发酵性染色质重塑复合物的一个亚基。我们表明,ARID1A 直接抑制 TERT,并且依赖于 SIN3 转录调节剂家族成员 A(SIN3A)抑制复合物对 TERT 启动子的 DNA 结合和共占据,从而允许 NB 分化进行。最后,使用 NB 患者队列的数据,我们报告了低 ARID1A 表达、TERT 表达升高与分化不良、高危 NB 之间存在显著相关性。这些结果提供了关于负责调节 TERT 驱动的 NB 进展的关键表观遗传途径的见解,这可能代表治疗干预的目标。